Kura Oncology's Ziftomenib Hits 96% CRc in Frontline AML, FIT-001 Data at 2026 Summit

Kura Oncology's menin inhibitor ziftomenib achieved high complete response rates and deep measurable residual disease (MRD) negativity in frontline acute myeloid leukemia, according to updated results from the Phase 1 KOMET-007 trial presented at the 2026 European Hematology Association Congress. The company also announced that updated Phase 1a data from its FIT-001 trial in advanced renal cell carcinoma will be featured in an oral presentation at the 2026 Kidney Cancer Research Summit. Ziftomenib's first full quarter of commercial availability as KOMZIFTI™ for relapsed or refractory NPM1-mutated AML generated $5.8 million in net product revenue.

In the KOMET-007 trial evaluating ziftomenib combined with intensive 7+3 chemotherapy in newly diagnosed NPM1-mutant or KMT2A-rearranged AML, the composite complete response rate reached 96% for NPM1-m and 90% for KMT2A-r disease. Among complete response achievers, MRD negativity was documented in 83% of NPM1-m and 82% of KMT2A-r patients. The 12-month overall survival estimate for the NPM1-m cohort was 94%, which the data indicated compares favorably to historical standard-of-care outcomes. These findings support the ongoing Phase 3 KOMET-017 trial.

Separately, the company disclosed that updated Phase 1a data from the FIT-001 trial, which investigates an unspecified candidate in advanced renal cell carcinoma, will be delivered as an oral presentation at the 2026 Kidney Cancer Research Summit. No trial results were included in the announcement.

The stock has exhibited mixed short-term performance: a 1-month share price return of 9.37% and a 90-day return of 11.04%, offset by a 7-day decline of 5.15%. The 1-year total shareholder return stands at 70.75%, though 3- and 5-year returns remain negative. Kura trades well below the average analyst price target; one prevailing narrative calculates a fair value of $31.17 per share against a last close of $10.86, implying the stock is 65% undervalued. Analyst targets range from $16.00 to $76.00, with a consensus average of $32.45, suggesting a potential upside of 278%. Analyst sentiment is overwhelmingly positive, with 13 buy ratings, 2 hold ratings, and no sell ratings.

Kura Oncology remains unprofitable, with ongoing losses of $294.57 million and an operating loss of $318 million over the last twelve months. The company is not cash flow generative: free cash flow was a negative $104.87 million, and cash flow from operations as a percentage of revenue was -109%. The price-to-sales ratio of 13.5x exceeds the US biotech industry average of 11.3x. Strategic collaborations with Novartis Pharma AG, Kyowa Kirin Co., Ltd., and Mirati Therapeutics, Inc. support pipeline programs targeting acute leukemias, head and neck squamous cell carcinoma, and non-small cell lung cancer. Key risks include heavy dependence on pivotal trial success and regulatory approval of ziftomenib. Short interest is 16%, and share-based compensation as a percentage of revenue reached 53% over the last twelve months.